Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications

Exp Mol Med. 2024 Feb;56(1):19-31. doi: 10.1038/s12276-023-01132-8. Epub 2024 Jan 4.

Abstract

Cancer immunotherapy has revolutionized the approach to cancer treatment of malignant tumors by harnessing the body's immune system to selectively target cancer cells. Despite remarkable advances, there are still challenges in achieving successful clinical responses. Recent evidence suggests that immune cell-derived exosomes modulate the immune system to generate effective antitumor immune responses, making them a cutting-edge therapeutic strategy. However, natural exosomes are limited in clinical application due to their low drug delivery efficiency and insufficient antitumor capacity. Technological advancements have allowed exosome modifications to magnify their intrinsic functions, load different therapeutic cargoes, and preferentially target tumor sites. These engineered exosomes exert potent antitumor effects and have great potential for cancer immunotherapy. In this review, we describe ingenious modification strategies to attain the desired performance. Moreover, we systematically summarize the tumor-controlling properties of engineered immune cell-derived exosomes in innate and adaptive immunity. Collectively, this review provides a comprehensive and intuitive guide for harnessing the potential of modified immune cell-derived exosome-based approaches, offering valuable strategies to enhance and optimize cancer immunotherapy.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity
  • Exosomes* / pathology
  • Humans
  • Immune System
  • Immunotherapy
  • Neoplasms* / pathology